Recombinant human Annexin A5 proteins (rhANXA5) are currently in clinical development as a potential therapeutic in RVO (ANXV, Phase 2a Safety and Proof of Concept Study, ClinicalTrials.gov Identifier: NCT05532735; Annexin Pharmaceuticals, Stockholm, Sweden) and in sepsis (SY-005; Phase 2a, ClinicalTrials.gov Identifier: NCT04898322; Yabao Pharmaceutical Group Co., Ltd., Yuncheng, China). This evidence concerns the gene ANXA5 and Sepsis.